A recent genomic classification in a large cohort of pediatric RMS showed that MYOD1 mutations occur in 3% of fusion-negative patients (where “fusion negative” includes tumors without the canonical PAX3::FOXO1 or PAX7::FOXO1 fusion, pathognomonic of ARMS) [18]. This evidence concerns the gene FOXO1 and alveolar rhabdomyosarcoma.